Sign in
CompletedPhase 3

Efficacy and Safety of Pitolisant in Pediatric Narcoleptic Patients With or Without Cataplexy, Double-blind Study Followed by a Prolonged Open-label Period

Key facts

Who runs it
Bioprojet
Where
Finland, France, Italy, Netherlands, and Russia9 sites in 5 countriesChoose a country to see its sites
Status
Completed
Phase
Phase 3
People taking part
110 people enrolled
Started
6 Jun 2016
Ended
5 Jun 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • pitolisant
  • Placebo
Record updated
26 June 2025

Who can take part

Age
6 years to 18 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Male and female children from 6 to less than 18 years of age suffering from narcolepsy with or without cataplexy - ICSD-3 criteria (narcolepsy type 1 and 2)
  • PDSS
  • Patients should be free of non-authorized medication, in particular psychostimulant treatments as from the screening visit onwards
  • Parents - and patients old enough to understand who have expressed a willingness to participate in the study, who have signed and dated the informed consent form prior to beginning protocol required procedures
  • In the opinion of the investigator, the patient must have adequate support to comply with the entire study requirements as described in the protocol (e.g., transportation to and from trial site, self rating scales and diaries completion, drug compliance, scheduled visits, tests)

Who cannot take part

  • Any other conditions that can be considered the primary causes of EDS
  • Psychiatric and neurological disorders in the investigator's opinion, would preclude the patient's participation and completion of this trial or comprise reliable representation of subjective symptoms
  • Active clinically significant illness, including unstable cardiovascular, endocrine, neoplastic, gastrointestinal, haematological, hepatic, immunologic, metabolic, neurological (other than narcolepsy/cataplexy), pulmonary, and/or renal disease which could interfere with the study conduct or counter-indicate the study treatments or place the patient at risk during the trial or compromise the study objectives
  • Any significant abnormality of the electrocardiogram and particularly Fridericia's QTc interval
  • Patients with significant abnormality or clinical laboratory results
  • Cataplectic patients treated by anticataplectics which are not under a stable treatment at the time of inclusion
  • Patients treated for cataplexy or any other pathology, by tricyclic antidepressants

Where is this trial?

It has sites in 5 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this multicenter double blind study is to assess efficacy and safety of Pitolisant versus placebo in paediatric Narcoleptic patients with or without cataplexy.

The 2 groups in the trial

  • pitolisantTreatment being tested

    tablet, oral, once a day.

  • placeboPlacebo, for comparison

    tablet, oral, once a day.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Double Blind, Multicentre, Randomized, Placebo-controlled Trial to Evaluate Safety and Efficacy of Pitolisant in Children From 6 to Less Than 18 Years With Narcolepsy With/Without Cataplexy, Followed by a Prolonged Open-label Period
Publications
Record updated
26 June 2025